Pancreatic cancer
Conditions
Interventions
Mechanism Research Group:None
Drug Testing Group:None
Sponsors
The Ninth Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pancreatic space-occupying lesions suggested by imaging examinations (CT/MRI/PET-CT) and abnormally elevated tumor markers (CA19-9 > 37 U/mL), with a high clinical suspicion of pancreatic cancer, who are planned to undergo EUS-FNB for a definitive diagnosis; 2. Aged 18-80 years, regardless of gender; 3. No contraindications related to EUS-FNB procedures (such as severe cardiopulmonary dysfunction, severe coagulation disorders, etc.); 4. Pancreatic lesions are newly discovered, and the patient has not received anti-tumor treatments targeting pancreatic cancer such as chemotherapy, targeted therapy, or radiotherapy; nor has the patient undergone pancreatic cancer surgery; 5. Willing to voluntarily sign the informed consent form, agree to provide tumor tissue obtained through EUS-FNB for organoid construction, and the patient and family are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who are pathologically confirmed to have non-pancreatic cancer (such as pancreatic neuroendocrine tumors, intraductal papillary mucinous neoplasms of the pancreas, etc.); 2. Patients who have malignant tumors in organs other than the pancreas, or who have serious major organ diseases such as heart, liver, or kidney disease, and are assessed by the investigator to have a life expectancy likely more influenced by these diseases than by pancreatic cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Organoid establishment success rate;First-line chemotherapy drug sensitivity rate;Inhibition rate of new drugs on growth; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ki-67; | — |
Countries
China
Contacts
Public ContactLianyong Li
The Ninth Medical Center of Chinese PLA General Hospital
Outcome results
None listed